Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M514Revenue (TTM) $M41.9Net Margin (%)-221.6Altman Z-Score1.7
Enterprise Value $M372EPS (TTM) $-1.2Operating Margin %-198.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.3Pre-tax Margin (%)-221.6Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %-8.4Quick Ratio4.6Cash flow > EarningsY
Price/Sales10.25-y EBITDA Growth Rate %6.0Current Ratio4.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-52.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-70.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M90.3ROIC % (ttm)-364.7Gross Margin Increase y-yN

Gurus Latest Trades with INO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

INO is held by these investors:



INO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Weiner David B.Director 2017-05-25Sell8,000$8-27.13view
Kim Jong JosephCEO 2017-03-31Sell147,180$6.54-10.86view
COLLINS MORTONDirector 2017-03-27Buy21,300$6.25-6.72view
Sardesai NiranjanCOO 2016-08-29Sell21,800$9.3-37.31view
COLLINS MORTONDirector 2016-06-28Buy10,000$9.13-36.14view
BENITO SIMON XDirector 2016-05-18Sell6,250$10.37-43.78view
COLLINS MORTONDirector 2016-04-15Buy68,400$9.52-38.76view
Sardesai NiranjanCOO 2015-09-30Buy4,000$5.56view
BENITO SIMON XDirector 2015-08-14Buy6,000$7.21-19.14view
Cabrera AngelDirector 2015-04-13Buy8,000$9.53-38.82view

Press Releases about INO :

Quarterly/Annual Reports about INO:

News about INO:

Articles On GuruFocus.com
Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Again Jan 22 2018 
Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Jan 17 2018 
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Developm Jan 09 2018 
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Tr Jan 08 2018 
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3 Jan 02 2018 
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development Dec 11 2017 
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors Dec 06 2017 
Detailed Research: Economic Perspectives on CVS Health, FirstEnergy, Welbilt, Inc., Rockwell Collins Dec 01 2017 
Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signat Nov 29 2017 
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synerg Nov 27 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK